Cellectar Biosciences Inc Working Capital to Net Assets Ratio
Cellectar Biosciences Inc working capital to net assets ratio. Cellectar Biosciences Inc (CLRB) has a Working Capital to Net Assets ratio of 93.6% as of December 2025. Working capital of $9.29 Million (current assets of $14.04 Million minus current liabilities of $4.75 Million) is measured against net assets of $9.92 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Cellectar Biosciences Inc to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Cellectar Biosciences Inc (2004–2025)
Working capital to net assets ratio of Cellectar Biosciences Inc from 2004 to 2025. This chart shows how Cellectar Biosciences Inc's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2004 to 2025. As of December 2025, the ratio stands at 93.6%, reflecting working capital of $9.29 Million against net assets of $9.92 Million USD. See CLRB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Cellectar Biosciences Inc Working Capital to Net Assets Ratio by Year (2004–2025)
Cellectar Biosciences Inc working capital to net assets ratio by year from 2004 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Cellectar Biosciences Inc from 2004 to 2025, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Cellectar Biosciences Inc.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 93.6% | $9.29 Million | $9.92 Million | $14.04 Million | $4.75 Million | ▼ -10.3 pp |
| 2024 | 104.0% | $14.86 Million | $14.29 Million | $24.25 Million | $9.39 Million | ▼ -4.2 pp |
| 2023 | 108.2% | $-14.91 Million | $-13.78 Million | $10.45 Million | $25.36 Million | ▲ +13.5 pp |
| 2022 | 94.7% | $9.03 Million | $9.54 Million | $20.53 Million | $11.50 Million | ▼ -3.9 pp |
| 2021 | 98.6% | $32.58 Million | $33.05 Million | $36.57 Million | $3.99 Million | ▼ -0.6 pp |
| 2020 | 99.2% | $54.38 Million | $54.79 Million | $57.94 Million | $3.56 Million | ▲ +4.1 pp |
| 2019 | 95.1% | $8.62 Million | $9.06 Million | $11.39 Million | $2.77 Million | ▲ +2.1 pp |
| 2018 | 93.0% | $12.33 Million | $13.26 Million | $13.95 Million | $1.62 Million | ▲ +15.3 pp |
| 2017 | 77.7% | $8.36 Million | $10.75 Million | $10.47 Million | $2.11 Million | ▼ -0.3 pp |
| 2016 | 78.0% | $10.56 Million | $13.54 Million | $12.19 Million | $1.63 Million | ▲ +170.3 pp |
| 2015 | -92.3% | $-1.52 Million | $1.65 Million | $4.18 Million | $5.70 Million | ▼ -124.5 pp |
| 2014 | 32.2% | $3.47 Million | $10.75 Million | $9.70 Million | $6.23 Million | ▲ +135.5 pp |
| 2013 | -103.3% | $-1.76 Million | $1.70 Million | $2.77 Million | $4.52 Million | ▼ -146.6 pp |
| 2012 | 43.3% | $4.40 Million | $10.16 Million | $5.13 Million | $732.69K | ▼ -12.7 pp |
| 2011 | 56.0% | $5.31 Million | $9.48 Million | $5.82 Million | $503.58K | ▼ -70.9 pp |
| 2010 | 126.9% | $1.53 Million | $1.21 Million | $2.44 Million | $904.82K | ▲ +96.8 pp |
| 2009 | 30.1% | $-8.10 Million | $-26.90 Million | $8.87 Million | $16.97 Million | ▼ -63.5 pp |
| 2008 | 93.6% | $-5.22 Million | $-5.58 Million | $1.39 Million | $6.62 Million | ▲ +161.7 pp |
| 2007 | -68.1% | $4.00 Million | $-5.87 Million | $11.06 Million | $7.06 Million | ▼ -167.8 pp |
| 2006 | 99.7% | $10.58 Million | $10.61 Million | $11.89 Million | $1.31 Million | ▲ +2.6 pp |
| 2005 | 97.1% | $4.58 Million | $4.72 Million | $4.80 Million | $217.16K | ▼ -2.7 pp |
| 2004 | 99.8% | $-4.34 Million | $-4.35 Million | $102.57K | $4.44 Million | — |